⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11078493 | 0.80 | CES2 (0.58) | — | |
| SCHEMBL15527129 | 0.76 | — | — | |
| SCHEMBL14664162 | 0.76 | — | — | |
| SCHEMBL247847 | 0.76 | — | — | |
| SCHEMBL4144993 | 0.76 | — | — | |
| SCHEMBL6006624 | 0.76 | — | — | |
| SCHEMBL1650571 | 0.76 | — | — | |
| SCHEMBL3059543 | 0.76 | — | — | |
| SCHEMBL15527758 | 0.74 | ALDH1A1 (0.54) | — | |
| Hydrochloric Acid SCHEMBL857460 | 0.74 | CES2 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3642209-B1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY Therapeutics LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023166232-A1 | COMPOUNDS DERIVED FROM 4-AMINO-N-(4-AMINOPHENYL)BENZAMIDE AND ANALOGUES AND USE THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2023-09-07 | — | — | WO | disclosed |
| US-20210408400-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-12-30 | — | — | US | disclosed |
| EP-3601273-B1 | 4-PIPERIDIN-N-(PYRIMIDIN-4-YL)CHROMAN-7-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | GENENTECH INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10790464-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-09-29 | — | — | US | disclosed |
| WO-2020107221-A1 | CHEMICAL ACTIVATORS OF NICOTINAMIDE MONONUCLEOTIDE ADENLYLY TRANSFERASE 2 (NMNAT2) AND USES THEREOF | TSINGHUA UNIVERSITY (CN) | 2020-06-04 | — | — | WO | disclosed |
| US-10550203-B2 | Polymers functionalized with heterocyclic nitrile compounds | BRIDGESTONE CORPORATION (JP) | 2020-02-04 | — | — | US | disclosed |
| EP-3542821-A1 | p53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | Tokyo University of Science Foundation (JP) | 2019-09-25 | — | — | EP | disclosed |
| WO-2019014460-A1 | EAAT2 ENHANCING MOLECULES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2019-01-17 | — | — | WO | disclosed |
| WO-2018092725-A1 | p53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | 学校法人東京理科大学 | 2018-05-24 | — | — | WO | disclosed |
| US-20170015760-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2017-01-19 | — | — | US | disclosed |
| US-20170015760-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2017-01-19 | — | — | US | disclosed |
| WO-2016123253-A1 | HYDRAZNE DERIVATIVES FOR THE TREATMENT OF CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-08-04 | — | — | WO | disclosed |
| US-9085646-B2 | Polymers functionalized with heterocyclic nitrile compounds | BRIDGESTONE CORPORATION (JP) | 2015-07-21 | — | — | US | disclosed |
| WO-2014081168-A1 | FLUORANTHENE COMPOUND, AND ORGANIC ELECTRONIC DEVICE COMPRISING SAME | 주식회사 엘지화학 (KR) | 2014-05-30 | — | — | WO | disclosed |
| US-20130066016-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2013-03-14 | — | — | US | disclosed |
| US-7915293-B2 | Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915293-B2 | Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| WO-2007087204-A2 | HETEROCYCLES AS NICOTINIC ACID RECEPTOR AGONISTS FOR THE TREATMENT OF DYYSLIPIDEMIA | SCHERING CORPOORATION (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2005007621-A2 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |